Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neoplasms 2Leukemia 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Respiratory Sounds 1Prostatic Neoplasms 1Pre-Eclampsia 1Postoperative Complications 1Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Myelodysplastic Syndromes 1Musculoskeletal Pain 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Liver Cirrhosis 1Lewy Body Disease 1Hypoxia 1Hodgkin Disease 1Hemorrhage 1Edema 1Dyspnea, Paroxysmal 1Dyspnea 1Drug-Related Side Effects and Adverse Reactions 1Congenital Hyperinsulinism 1Breast Neoplasms 1Advanced Solid Malignancies 1

Interventions

fluorodopa F 18 1Referral and Consultation 1Neurofeedback 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lewy Body Disease × Furosemide × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡